Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Application
Filed:
July 27, 2023
Publication date:
February 15, 2024
Applicants:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Grant
Filed:
April 5, 2021
Date of Patent:
August 22, 2023
Assignees:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development
Co. Ltd.
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Application
Filed:
April 5, 2021
Publication date:
July 22, 2021
Applicants:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Grant
Filed:
April 19, 2020
Date of Patent:
May 4, 2021
Assignees:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Application
Filed:
April 19, 2020
Publication date:
October 22, 2020
Applicants:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz